FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944448730> ?p ?o ?g. }

• W2944448730 endingPage "45" @default.
• W2944448730 startingPage "40" @default.
• W2944448730 abstract "Background and aims Patients with familial hypercholesterolaemia (FH) may require proprotein convertase subtilisin/kexin-type 9 (PCSK9) mAb as add-on therapy to achieve LDL-cholesterol (LDL-C) goals. However, the current cost of these therapies means that choosing suitable patients is based on consensus or clinical judgement rather than a quantitative risk assessment. We used the SAFEHEART Risk Equation (RE) to estimate the number needed to treat (NNT) at different risk thresholds and baseline LDL-C to identify those FH patients more likely to derive the greatest benefit from PCSK9 mAb. Methods Five-year event rates were calculated using the SAFEHEART-RE for every patient, overall and across LDL-C strata. A 60% reduction of LDL-C after theoretical treatment with PCSK9 mAb was assumed. Individual absolute risk simulating the effects of PCSK9 inhibition was calculated using the SAFEHEART-RE and, in a similar way, by using the Cholesterol Treatment Trialists’ (CTT) Collaboration criteria. Absolute risk reduction and NNTs were calculated. Results Of the total SAFEHEART population, 2,153 were FH cases aged 18 years or older, on maximum tolerated lipid lowering treatment. NNTs were dependent of both baseline predicted risk and baseline LDL-C level ranging from 44 to 17 for those with 5-year risk of ≥1 to ≥5. The smallest NNT (12) was observed among those with 5-year risk of ≥5% and LDL-C ≥160 mg/dl. Using the CTT criteria produced similar results. Conclusions The SAFEHEART-RE may provide a useful quantitative tool for rationalising the selection of FH patients who might derive greater absolute benefits from PCSK9 mAb." @default.
• W2944448730 created "2019-05-16" @default.
• W2944448730 creator A5004801541 @default.
• W2944448730 creator A5006206326 @default.
• W2944448730 creator A5018981107 @default.
• W2944448730 creator A5053901502 @default.
• W2944448730 creator A5058100820 @default.
• W2944448730 creator A5070499961 @default.
• W2944448730 creator A5072747894 @default.
• W2944448730 creator A5079564889 @default.
• W2944448730 creator A5089419937 @default.
• W2944448730 creator A5091523473 @default.
• W2944448730 date "2019-07-01" @default.
• W2944448730 modified "2023-10-16" @default.
• W2944448730 title "Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia" @default.
• W2944448730 cites W1844854928 @default.
• W2944448730 cites W1990132833 @default.
• W2944448730 cites W2014561045 @default.
• W2944448730 cites W2024930123 @default.
• W2944448730 cites W2049308410 @default.
• W2944448730 cites W2106671991 @default.
• W2944448730 cites W2247997571 @default.
• W2944448730 cites W2298508936 @default.
• W2944448730 cites W2302032525 @default.
• W2944448730 cites W2405171365 @default.
• W2944448730 cites W2410774145 @default.
• W2944448730 cites W2511907480 @default.
• W2944448730 cites W2552653484 @default.
• W2944448730 cites W2557044136 @default.
• W2944448730 cites W2559619119 @default.
• W2944448730 cites W2564712078 @default.
• W2944448730 cites W2596179513 @default.
• W2944448730 cites W2609543937 @default.
• W2944448730 cites W2620146310 @default.
• W2944448730 cites W2731425052 @default.
• W2944448730 cites W2744832038 @default.
• W2944448730 cites W2771919228 @default.
• W2944448730 cites W2790951009 @default.
• W2944448730 cites W2796045420 @default.
• W2944448730 cites W2800105293 @default.
• W2944448730 cites W2800876320 @default.
• W2944448730 cites W2894591464 @default.
• W2944448730 doi "https://doi.org/10.1016/j.atherosclerosis.2019.05.003" @default.
• W2944448730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31100618" @default.
• W2944448730 hasPublicationYear "2019" @default.
• W2944448730 type Work @default.
• W2944448730 sameAs 2944448730 @default.
• W2944448730 citedByCount "7" @default.
• W2944448730 countsByYear W29444487302019 @default.
• W2944448730 countsByYear W29444487302020 @default.
• W2944448730 countsByYear W29444487302021 @default.
• W2944448730 countsByYear W29444487302023 @default.
• W2944448730 crossrefType "journal-article" @default.
• W2944448730 hasAuthorship W2944448730A5004801541 @default.
• W2944448730 hasAuthorship W2944448730A5006206326 @default.
• W2944448730 hasAuthorship W2944448730A5018981107 @default.
• W2944448730 hasAuthorship W2944448730A5053901502 @default.
• W2944448730 hasAuthorship W2944448730A5058100820 @default.
• W2944448730 hasAuthorship W2944448730A5070499961 @default.
• W2944448730 hasAuthorship W2944448730A5072747894 @default.
• W2944448730 hasAuthorship W2944448730A5079564889 @default.
• W2944448730 hasAuthorship W2944448730A5089419937 @default.
• W2944448730 hasAuthorship W2944448730A5091523473 @default.
• W2944448730 hasBestOaLocation W29444487302 @default.
• W2944448730 hasConcept C120195587 @default.
• W2944448730 hasConcept C126322002 @default.
• W2944448730 hasConcept C2778114629 @default.
• W2944448730 hasConcept C2778163477 @default.
• W2944448730 hasConcept C2779120738 @default.
• W2944448730 hasConcept C2780072125 @default.
• W2944448730 hasConcept C2780745583 @default.
• W2944448730 hasConcept C2780948078 @default.
• W2944448730 hasConcept C2908647359 @default.
• W2944448730 hasConcept C43554185 @default.
• W2944448730 hasConcept C44249647 @default.
• W2944448730 hasConcept C67774102 @default.
• W2944448730 hasConcept C71924100 @default.
• W2944448730 hasConcept C82789193 @default.
• W2944448730 hasConcept C99454951 @default.
• W2944448730 hasConceptScore W2944448730C120195587 @default.
• W2944448730 hasConceptScore W2944448730C126322002 @default.
• W2944448730 hasConceptScore W2944448730C2778114629 @default.
• W2944448730 hasConceptScore W2944448730C2778163477 @default.
• W2944448730 hasConceptScore W2944448730C2779120738 @default.
• W2944448730 hasConceptScore W2944448730C2780072125 @default.
• W2944448730 hasConceptScore W2944448730C2780745583 @default.
• W2944448730 hasConceptScore W2944448730C2780948078 @default.
• W2944448730 hasConceptScore W2944448730C2908647359 @default.
• W2944448730 hasConceptScore W2944448730C43554185 @default.
• W2944448730 hasConceptScore W2944448730C44249647 @default.
• W2944448730 hasConceptScore W2944448730C67774102 @default.
• W2944448730 hasConceptScore W2944448730C71924100 @default.
• W2944448730 hasConceptScore W2944448730C82789193 @default.
• W2944448730 hasConceptScore W2944448730C99454951 @default.
• W2944448730 hasFunder F4320323479 @default.
• W2944448730 hasFunder F4320334923 @default.
• W2944448730 hasLocation W29444487301 @default.
• W2944448730 hasLocation W29444487302 @default.

• next